Lupus nephritis secondary prevention: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| Line 11: | Line 11: | ||
==Secondary Prevention== | ==Secondary Prevention== | ||
Aims of secondary prevention measures for SLE include:<ref name="pmid22593636">{{cite journal |vauthors=Maidhof W, Hilas O |title=Lupus: an overview of the disease and management options |journal=P T |volume=37 |issue=4 |pages=240–9 |date=April 2012 |pmid=22593636 |pmc=3351863 |doi= |url=}}</ref><ref name="pmid10782816">{{cite journal |vauthors=Zangger P, Gladman DD, Urowitz MB, Bogoch ER |title=Outcome of total hip replacement for avascular necrosis in systemic lupus erythematosus |journal=J. Rheumatol. |volume=27 |issue=4 |pages=919–23 |year=2000 |pmid=10782816 |doi= |url=}}</ref> | |||
* Preventing [[glucocorticoid]] usage and using the minimum dosage to prevent [[osteonecrosis]] and [[Osteoporosis|osteoprosis]] side effects | |||
* | * Decreasing [[Atherosclerosis|atherosclerotic]] events in patients | ||
**[ | ** Low doses of [[aspirin]] | ||
**[ | ** [[ACE inhibitor|ACE inhibitors]] | ||
**[ | ** [[Statins]] | ||
* For prevention and/or early diagnosis of [[malignancies]]: | |||
** Regular age-related specific [[cancer screening]] recommended for the general population | |||
==References== | ==References== | ||
Revision as of 17:18, 20 July 2018
|
Lupus nephritis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Lupus nephritis secondary prevention On the Web |
|
American Roentgen Ray Society Images of Lupus nephritis secondary prevention |
|
Risk calculators and risk factors for Lupus nephritis secondary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:
Overview
There are no established measures for the secondary prevention of [disease name].
OR
Effective measures for the secondary prevention of [disease name] include [strategy 1], [strategy 2], and [strategy 3].
Secondary Prevention
Aims of secondary prevention measures for SLE include:[1][2]
- Preventing glucocorticoid usage and using the minimum dosage to prevent osteonecrosis and osteoprosis side effects
- Decreasing atherosclerotic events in patients
- Low doses of aspirin
- ACE inhibitors
- Statins
- For prevention and/or early diagnosis of malignancies:
- Regular age-related specific cancer screening recommended for the general population
References
- ↑ Maidhof W, Hilas O (April 2012). "Lupus: an overview of the disease and management options". P T. 37 (4): 240–9. PMC 3351863. PMID 22593636.
- ↑ Zangger P, Gladman DD, Urowitz MB, Bogoch ER (2000). "Outcome of total hip replacement for avascular necrosis in systemic lupus erythematosus". J. Rheumatol. 27 (4): 919–23. PMID 10782816.